Skip Navigation LinksFocus

Current Edition                                                                                  

Monitoring Anti-TNF-α Therapies in Chronic Inflammatory Disorders: Infliximab and Adalimumab

Date: November 2016

Anti-tumour necrosis factor (anti-TNF) therapy has, since the 1990s, become an important part of the management of several chronic inflammatory diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ankylosing spondylitis and severe psoriasis. The first anti-TNF drug to be approved for clinical use was infliximab; since then several more have been developed including adalimumab, golimumab, and etanercept.

Click here to access the full article »

 

 

 

 

 

 

 

Previous Editions

FOCUS